Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 2
1971 1
1972 1
1974 2
1976 5
1978 3
1979 10
1980 7
1981 3
1982 6
1983 6
1984 3
1985 13
1986 8
1987 4
1988 8
1989 9
1990 8
1991 12
1992 17
1993 14
1994 23
1995 15
1996 21
1997 18
1998 27
1999 22
2000 44
2001 38
2002 27
2003 47
2004 51
2005 53
2006 63
2007 64
2008 59
2009 68
2010 69
2011 74
2012 83
2013 93
2014 98
2015 96
2016 149
2017 180
2018 191
2019 179
2020 195
2021 182
2022 195
2023 180
2024 75

Text availability

Article attribute

Article type

Publication date

Search Results

2,493 results

Results by year

Filters applied: . Clear all
Page 1
Huntington's disease: diagnosis and management.
Stoker TB, Mason SL, Greenland JC, Holden ST, Santini H, Barker RA. Stoker TB, et al. Pract Neurol. 2022 Feb;22(1):32-41. doi: 10.1136/practneurol-2021-003074. Epub 2021 Aug 19. Pract Neurol. 2022. PMID: 34413240 Review.
Huntington's disease (HD) is an inherited neurodegenerative disease characterised by neuropsychiatric symptoms, a movement disorder (most commonly choreiform) and progressive cognitive impairment. ...Current treatments are symptomatic, and largely directed at the ch …
Huntington's disease (HD) is an inherited neurodegenerative disease characterised by neuropsychiatric symptoms, a movement disorde …
Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.
Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C; the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Seppi K, et al. Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Mov Disord. 2019. PMID: 30653247 Free PMC article. Review.
OBJECTIVE: To update evidence-based medicine recommendations for treating nonmotor symptoms in Parkinson's disease (PD). BACKGROUND: The International Parkinson and Movement Disorder Society Evidence-Based Medicine Committee's recommendations for treatments of PD we …
OBJECTIVE: To update evidence-based medicine recommendations for treating nonmotor symptoms in Parkinson's disease (PD). BACKGROUND: The Int …
International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C; Movement Disorder Society Evidence-Based Medicine Committee. Fox SH, et al. Mov Disord. 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23. Mov Disord. 2018. PMID: 29570866 Review.
Criteria for inclusion and quality scoring were as previously reported. Five clinical indications were considered, and conclusions regarding the implications for clinical practice are reported. ...These recommendations allow the treating physician to determine which …
Criteria for inclusion and quality scoring were as previously reported. Five clinical indications were considered, and conclusions re …
GLP-1 receptor agonists for Parkinson's disease.
Mulvaney CA, Duarte GS, Handley J, Evans DJ, Menon S, Wyse R, Emsley HC. Mulvaney CA, et al. Cochrane Database Syst Rev. 2020 Jul 23;7(7):CD012990. doi: 10.1002/14651858.CD012990.pub2. Cochrane Database Syst Rev. 2020. PMID: 32700772 Free PMC article.
The most recent search was run on 25 June 2020. SELECTION CRITERIA: We included randomised controlled trials (RCTs) of adults with PD that compared GLP-1 receptor agonists with conventional PD treatment, placebo, or no treatment. ...Exenatide versus placebo Primary outcome …
The most recent search was run on 25 June 2020. SELECTION CRITERIA: We included randomised controlled trials (RCTs) of adults with PD …
Trial of Cinpanemab in Early Parkinson's Disease.
Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, Rascol O, Giladi N, Stocchi F, Tanner CM, Postuma RB, Simon DK, Tolosa E, Mollenhauer B, Cedarbaum JM, Fraser K, Xiao J, Evans KC, Graham DL, Sapir I, Inra J, Hutchison RM, Yang M, Fox T, Budd Haeberlein S, Dam T; SPARK Investigators. Lang AE, et al. N Engl J Med. 2022 Aug 4;387(5):408-420. doi: 10.1056/NEJMoa2203395. N Engl J Med. 2022. PMID: 35921450 Clinical Trial.
Cinpanemab, a human-derived monoclonal antibody that binds to alpha-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease. METHODS: In a 52-week, multicenter, double-blind, phase 2 trial, we randomly assigned, in a 2:1:2:2 ratio, par …
Cinpanemab, a human-derived monoclonal antibody that binds to alpha-synuclein, is being evaluated as a disease-modifying treatment for Parki …
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF. Hauser RA, et al. Am J Psychiatry. 2017 May 1;174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037. Epub 2017 Mar 21. Am J Psychiatry. 2017. PMID: 28320223 Clinical Trial.
OBJECTIVE: Tardive dyskinesia is a persistent movement disorder induced by dopamine receptor blockers, including antipsychotics. ...This phase 3 study further evaluated the efficacy, safety, and tolerability of valbenazine as a treatment for tardive dyskinesia. METH …
OBJECTIVE: Tardive dyskinesia is a persistent movement disorder induced by dopamine receptor blockers, including antipsychotic …
Maintenance treatment with antipsychotic drugs for schizophrenia.
Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM, Leucht S. Ceraso A, et al. Cochrane Database Syst Rev. 2020 Aug 11;8(8):CD008016. doi: 10.1002/14651858.CD008016.pub3. Cochrane Database Syst Rev. 2020. PMID: 32840872 Free PMC article.
For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CIs) on an intention-to-treat basis based on a random-effects model. For continuous data, we calculated mean differences (MD) or standardised mean differences (SMD), again based on a …
For dichotomous data we calculated risk ratios (RR) and their 95% confidence intervals (CIs) on an intention-to-treat basis based on a ra …
Magnesium supplementation for the treatment of restless legs syndrome and periodic limb movement disorder: A systematic review.
Marshall NS, Serinel Y, Killick R, Child JM, Raisin I, Berry CM, Lallukka T, Wassing R, Lee RW, Ratnavadivel R, Vedam H, Grunstein R, Wong KK, Hoyos CM, Cayanan EA, Comas M, Chapman JL, Yee BJ. Marshall NS, et al. Sleep Med Rev. 2019 Dec;48:101218. doi: 10.1016/j.smrv.2019.101218. Epub 2019 Oct 16. Sleep Med Rev. 2019. PMID: 31678660
Magnesium supplementation is often suggested for restless legs syndrome (RLS) or period limb movement disorder (PLMD) based on anecdotal evidence that it relieves symptoms and because it is also commonly recommended for leg cramps. ...Seven full-text articles were u …
Magnesium supplementation is often suggested for restless legs syndrome (RLS) or period limb movement disorder (PLMD) based on …
A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.
den Heijer JM, Kruithof AC, Moerland M, Walker M, Dudgeon L, Justman C, Solomini I, Splitalny L, Leymarie N, Khatri K, Cullen VC, Hilt DC, Groeneveld GJ, Lansbury P. den Heijer JM, et al. Mov Disord. 2023 Jul;38(7):1197-1208. doi: 10.1002/mds.29346. Epub 2023 May 17. Mov Disord. 2023. PMID: 37195859 Clinical Trial.
OBJECTIVES: This first-in-patient study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of 28 daily doses of LTI-291 in GBA-PD. METHODS: This was a randomized, double-blind, placebo-controlled trial in 40 GBA-PD participants. ...Movement D …
OBJECTIVES: This first-in-patient study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of 28 daily doses of LTI- …
Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial.
Parkinson Study Group SURE-PD3 Investigators; Schwarzschild MA, Ascherio A, Casaceli C, Curhan GC, Fitzgerald R, Kamp C, Lungu C, Macklin EA, Marek K, Mozaffarian D, Oakes D, Rudolph A, Shoulson I, Videnovic A, Scott B, Gauger L, Aldred J, Bixby M, Ciccarello J, Gunzler SA, Henchcliffe C, Brodsky M, Keith K, Hauser RA, Goetz C, LeDoux MS, Hinson V, Kumar R, Espay AJ, Jimenez-Shahed J, Hunter C, Christine C, Daley A, Leehey M, de Marcaida JA, Friedman JH, Hung A, Bwala G, Litvan I, Simon DK, Simuni T, Poon C, Schiess MC, Chou K, Park A, Bhatti D, Peterson C, Criswell SR, Rosenthal L, Durphy J, Shill HA, Mehta SH, Ahmed A, Deik AF, Fang JY, Stover N, Zhang L, Dewey RB Jr, Gerald A, Boyd JT, Houston E, Suski V, Mosovsky S, Cloud L, Shah BB, Saint-Hilaire M, James R, Zauber SE, Reich S, Shprecher D, Pahwa R, Langhammer A, LaFaver K, LeWitt PA, Kaminski P, Goudreau J, Russell D, Houghton DJ, Laroche A, Thomas K, McGraw M, Mari Z, Serrano C, Blindauer K, Rabin M, Kurlan R, Morgan JC, Soileau M, Ainslie M, Bodis-Wollner I, Schneider RB, Waters C, Ratel AS, Beck CA, Bolger P, Callahan KF, Crotty GF, Klements D, Kostrzebski M, McMahon GM, Pothier L, Waikar SS, Lang A, Mestre T. Parkinson Study Group SURE-PD3 Investigators, et al. JAMA. 2021 Sep 14;326(10):926-939. doi: 10.1001/jama.2021.10207. JAMA. 2021. PMID: 34519802 Free PMC article. Clinical Trial.
DESIGN, PARTICIPANTS, AND SETTING: Randomized, double-blind, placebo-controlled, phase 3 trial of oral inosine treatment in early PD. ...TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02642393....
DESIGN, PARTICIPANTS, AND SETTING: Randomized, double-blind, placebo-controlled, phase 3 trial of oral inosine treatment in ea …
2,493 results